DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Asperger syndrome — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAsperger syndrome maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for asperger syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
neuroligin 4 X-linked (NLGN4X) — NLGN4X is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet flcdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3BE8 · 2.2 Å · ligand CITRATE ANION (FLC). Experimental structure, not a prediction.
What the evidence adds up to
No abstract in this set reports a drug trial or any pharmacological intervention for Asperger syndrome. The 2003 review notes that clinical research has produced mixed results that do not clearly discriminate Asperger syndrome from high-functioning autism, and that children with pervasive developmental disorder achieve better outcomes when diagnosis is made early and appropriate community supports can be marshalled. No drug, dose, response rate, or survival figure appears in any of the four abstracts.
The 2002 review states that outcome in Asperger syndrome is very variable: many individuals with the characteristic childhood pattern function well in adult age, though personality traits tend to be highly persistent; others have a very poor prognosis from the psychosocial adjustment point of view and cannot manage independently. The 2007 article lists employment issues, comorbid mental and physical health conditions, neurological issues, possible problems with the legal system, and mortality rates as areas of concern, but provides no numerical data on any of these.
The 2002 background factors abstract says the cause has not been definitely established, that a genetic contribution is clearly important in many cases, that some cases have been linked to brain damage or developmental abnormalities arising in foetal life or early years, and that psychosocial factors appear to contribute little to causing the syndrome but may be very important for outcome.
What is still missing from the literature represented here is any controlled trial of a drug for Asperger syndrome, any quantitative outcome measure (response rate, survival, or standardised symptom score), any patient stratification by biomarker or genetic subtype, and any funding for such trials. Without these, no evidence exists to support or refute any pharmacological treatment for the condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Focus on Autism and Other Developmental Disabilities · 2007 · 163 citations
Outcomes in Adults With Asperger Syndrome
AbstractThis article explores the current research literature on adult outcomes of individuals With Asperger syndrome (AS). Specific areas addressed are the characteristics associated With adulthood AS, including employment issues, comorbid mental and physical health conditions, neurological issues, possible problems With the legal system, mortality rates, and treatment. The article interWeaves the author's experiences as a parent of an adult son With AS and discusses recommendations and future directions.
Brazilian Journal of Psychiatry · 2003 · 50 citations · open access
Asperger syndrome: an update
AbstractThis article provides an overview of the history and clinical features of Asperger syndrome, and considers guidelines for clinical assessment and treatment. A review of issues related to external validity is provided, which points out the limitations of current research, and lists several potentially beneficial areas of investigation into the nosologic status of the condition. It concludes with a discussion of the unequivocal need of individuals with severe social disabilities for comprehensive and adequate educational services and other treatments irrespective of the fact that the validity and the utility of this specific diagnostic concept is far from resolved.
Current Opinion in Pediatrics · 2003 · 22 citations
Asperger syndrome: to be or not to be?
AbstractPURPOSE OF REVIEW: Asperger syndrome is a pervasive developmental disorder characterized by impairments in social interactions, such as nonverbal behaviors, failure to develop peer relationships, and lack of social reciprocity with restricted, repetitive and stereotyped patterns of interest or behavior. The diagnosis of Asperger syndrome is increasingly common, and it is timely to review its phenomenology and treatment. RECENT FINDINGS: As there is a growing public awareness and acceptance of Asperger syndrome, clinical research has produced mixed results that do not clearly discriminate Asperger syndrome from high-functioning autism. However, research does indicate that children with pervasive developmental disorder achieve better outcomes when diagnosis is made early and appropriate community supports can be marshaled. SUMMARY: The history and phenomenology of Asperger syndrome is briefly reviewed, and recent literature relating to assessment and treatment is highlighted.
Cambridge University Press eBooks · 2002 · 0 citations
Outcome in the longer term: adults with Asperger syndrome
AbstractOutcome in Asperger syndrome is very variable. Many of those with a characteristic pattern of problems in childhood are functioning well in adult age, even though the personality traits that were evident early on tend to be highly persistent. Others have a very poor prognosis from the psychosocial adjustment point of view and cannot manage independently in adult life. Others function along a spectrum in between excellent and highly restricted outcomes.
Cambridge University Press eBooks · 2002 · 0 citations
Background factors
AbstractIt has not yet been definitely established what causes Asperger syndrome. A genetic contribution is clearly important in many cases. Some cases have been linked to damage or developmental abnormalities in the brain arising either in foetal life or in the first years after birth. It is possible that some instances of the syndrome are attributable to the combination of genetic and brain damaging events. Psychosocial factors in themselves appear to contribute little in terms of causing the syndrome, but may be very important from the point of view of outcome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
